The CASP9 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population generated from the human liver adenocarcinoma cell line SK-HEP-1, featuring disruption of the CASP9 gene encoding the initiator caspase-9. This loss-of-function model enables investigation of intrinsic apoptosis signaling in a hepatocellular carcinoma background. The polyclonal format provides a heterogeneous knockout pool, ideal for population-level studies of apoptotic responses without clonal bias.
SK-HEP-1 cells, isolated from ascitic fluid of a patient with liver adenocarcinoma, display epithelial morphology and serve as a well-characterized model for hepatocellular carcinoma. Widely employed in cancer biology, these cells facilitate examination of hepatocarcinogenesis, metastatic behavior, and therapeutic resistance. The genetic environment of SK-HEP-1 supports the study of liver-specific signaling networks in the context of CASP9 disruption.
Caspase-9 acts as the apical initiator caspase of the intrinsic apoptotic pathway. In response to apoptotic stimuli, BAX/BAK-mediated mitochondrial outer membrane permeabilization releases cytochrome c, which binds Apaf-1 to assemble the apoptosome and recruit procaspase-9. Autocatalytic activation of caspase-9 then cleaves and activates effector caspases CASP3 and CASP7, leading to proteolysis of downstream substrates like PARP and ICAD. Regulation occurs at multiple levels: p53 transcriptionally upregulates caspase-9, XIAP directly inhibits caspase-9, and SMAC/Diablo relieves this inhibition. Disruption of CASP9 in these polyclonal cells abrogates signal transduction from the apoptosome to effector caspases, thereby blocking progression of the intrinsic apoptotic cascade.
In SK-HEP-1 hepatocellular carcinoma cells, CASP9 knockout mimics a key apoptosis evasion mechanism commonly observed in cancer. Many chemotherapeutics rely on intrinsic apoptosis to eliminate tumor cells; therefore, this model is valuable for dissecting caspase-9-dependent drug sensitivity and for studying alternative cell death pathways. Comparative analyses of wild-type and knockout populations can reveal strategies to overcome apoptotic resistance.
These knockout cells are suited for Western blot analysis of caspase-9 and its downstream substrates, such as cleaved CASP3 and PARP. Caspase activity assays using specific substrates quantitatively measure initiator and effector caspase function, while Annexin V staining by flow cytometry detects apoptosis induction. Cytochrome c release assays confirm maintenance of upstream mitochondrial events, and cell viability assays support drug screening. These applications make the product a versatile tool for apoptosis research, cancer biology, and therapeutic development. For further information, please contact Ascent Research.
